Corner Therapeutics, an immunotherapy company
pioneering novel vaccines, announced that it has raised $54 million to create vaccines that confer lifelong protection from cancer and infectious diseases.

The funding, led by Ziff Capital Partners and including Cockrell Interests, Tanis Ventures, and Sandia Holdings, will boost Corner's mission to enable the immune system to engineer long-living, disease-fighting T cells.